Novocellus Update

RNS Number : 1638S
Angle PLC
16 November 2011
 



For immediate release

16 November 2011

 

ANGLE plc ("the Company")

 

Novocellus Update

 

 

ANGLE plc (AIM:AGL) provides an update on Novocellus, its 82% owned portfolio company which specialises in IVF embryo viability. 

 

Novocellus has a partnership with Origio, a leading supplier of IVF culture medium, whereby Origio are responsible for undertaking the final trials for Novocellus' embryo viability product, EmbryoSure®.  Origio then have the right to license the EmbryoSure® IP in exchange for milestone payments and a 25% royalty on future sales. 

 

As previously advised to the market, the trial of EmbryoSure is delayed.  The timeframe for completing the trials is at present uncertain. ANGLE is meeting with Origio at the end of this month to review options for progressing the trials.  ANGLE remains confident of the potential for EmbryoSure to make a major impact in the IVF market. 

 

A further announcement will be made once the position becomes clearer. 

 

 

ANGLE Founder and Chief Executive, Andrew Newland, commented:

"We continue to believe that EmbryoSure has the potential to make a major impact in the IVF market and it is important to us that we get the trials completed and the product in the market as quickly as possible."

 

 

 

For further information:

 

ANGLE plc

01483 685830

Andrew Newland, Chief Executive

Ian Griffiths, Finance Director

 


Cenkos Securities

Stephen Keys, Adrian Hargrave (Nominated adviser)

Andy Roberts (Sales)

 

020 7397 8900

Buchanan

Lisa Baderoon

 

020 7466 5000

Scott Harris

Stephen Scott, Harry Dee

0207 653 0030

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCBRBDBSSBBGBU

Companies

Angle (AGL)
UK 100